Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 314

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 314
---
 when entering into the plan, without further direction from them. The director or executive officer may amend a Rule 10b5-1 plan in some
circumstances and may terminate a Rule 10b5-1 plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule 10b5-1 plan
when they are not in possession of material nonpublic information, or MNPI subject to compliance with the terms of our insider trading policy and any applicable 10b5-1
guidelines.

Policies and Practices Related to the Grant of Certain Equity Awards

From time to time, we grant stock options to our employees, including the named executive officers, and to our
non-employee directors. Historically, we have granted new-hire option awards on or soon after a new-hire’s employment start
date and refresh, promotion or retention option grants when and as determined by our board of directors. We do not maintain any written policies on the timing of awards of stock options or similar instruments with option-like features. Following the
effective date of the registration statement of which this prospectus forms a part, we expect that (i) the board of directors will consider whether there is any MNPI about us when determining the timing of stock option grants and will not seek
to time the award of stock options in relation to our public disclosure of MNPI and (ii) we will not time the public release of MNPI for the purpose of affecting the value of executive compensation.

209

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS Other than compensation arrangements for our directors and executive officers, which are described elsewhere in this prospectus, below we describe transactions since January 1, 2022 to which we were or will be a participant, in which:

| • |     | the amount involved in the transaction exceeded or will exceed the lesser of (i) $120,000 and (ii) 1% of the 
 average of our total assets as of the end of the last two completed fiscal years; and                        |

| • |     | any of our then directors, executive officers, or holders of more than 5% of our capital stock, or any member of                                                                                                     
 the immediate family of, or person sharing the household with, any of these individuals or entities, which we collectively refer to as our related parties, had or will have a direct or indirect material interest. |

Convertible Preferred Stock Financings Series C Preferred Stock Financing From